| 1 |
Grzych G, Bernard L, Lestrelin R, Tailleux A, Staels B. [State of the art on the pathophysiology, diagnosis and treatment of non-alcoholic steatohepatitis (NASH)]. Ann Pharm Fr 2023;81:183-201. [PMID: 36126753 DOI: 10.1016/j.pharma.2022.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Suplotovа LA, Kulmametova DS, Fedorova AI, Dushina TS, Makarova OB. Effect of sodium-glucose cotransporter type 2 inhibitors on non-alcoholic fatty liver disease. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-15-83-89] [Reference Citation Analysis]
|
| 3 |
Sun W, Xing Y, Kong D, Zhang Z, Ma H, Yang L. Meta-analysis of the effect of sodium-dependent glucose transporter 2 inhibitors on C-reactive protein in type 2 diabetes. Medicine (Baltimore) 2022;101:e30553. [PMID: 36197267 DOI: 10.1097/MD.0000000000030553] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Shaaban HH, Alzaim I, El-Mallah A, Aly RG, El-Yazbi AF, Wahid A. Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms. Life Sci 2022;308:120956. [PMID: 36103959 DOI: 10.1016/j.lfs.2022.120956] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 5 |
Polyzos SA, Goulis DG, Giouleme O, Germanidis GS, Goulas A. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Curr Obes Rep 2022;11:166-79. [PMID: 35501557 DOI: 10.1007/s13679-022-00474-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 6 |
Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
|
| 7 |
Ghosh A, Dutta K, Bhatt SP, Gupta R, Tyagi K, Ansari IA, Venugopal VK, Mahajan H, Pandey RM, Pandey S, Misra A. Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India. J Clin Endocrinol Metab 2022;107:e2267-75. [PMID: 35263436 DOI: 10.1210/clinem/dgac138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 8 |
Hussain M, Babar MZM, Tariq S, Ahmad MI, Akhtar L. Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients. Int J Diabetes Dev Ctries 2022;42:290-296. [DOI: 10.1007/s13410-021-00980-2] [Reference Citation Analysis]
|
| 9 |
Yen FS, Hsu CC, Wei JC, Hou MC, Hwu CM. Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. Front Med (Lausanne) 2022;9:839456. [PMID: 35252271 DOI: 10.3389/fmed.2022.839456] [Reference Citation Analysis]
|
| 10 |
Prikhodko VA, Bezborodkina NN, Okovityi SV. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022;10:274. [DOI: 10.3390/biomedicines10020274] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 11 |
Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 12 |
Zhang X, Zhao Y, Chen S, Shao H. Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. J Cachexia Sarcopenia Muscle 2021;12:1368-79. [PMID: 34676695 DOI: 10.1002/jcsm.12838] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 13 |
Phrueksotsai S, Pinyopornpanish K, Euathrongchit J, Leerapun A, Phrommintikul A, Buranapin S, Chattipakorn N, Thongsawat S. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:2952-9. [PMID: 34129252 DOI: 10.1111/jgh.15580] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 14 |
Massimino E, Izzo A, Riccardi G, Della Pepa G. The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms. Cells 2021;10:1958. [PMID: 34440727 DOI: 10.3390/cells10081958] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 15 |
Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64:1461-79. [PMID: 33877366 DOI: 10.1007/s00125-021-05442-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 16 |
Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 17 |
Song T, Chen S, Zhao H, Wang F, Song H, Tian D, Yang Q, Qi L. Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Hepatol Res 2021;51:641-51. [PMID: 33847462 DOI: 10.1111/hepr.13645] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 18 |
Lee KW, Devaraj NK, Ching SM, Veettil SK, Hoo FK, Deuraseh I, Soo MJ. Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials. Oman Med J 2021;36:e273. [PMID: 34239714 DOI: 10.5001/omj.2021.62] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 19 |
Das C, Tripathy D, Swain S, Sudhakaran N, Uthansingh K, Mallick P, Pati GK. Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey. Cureus 2021;13:e14974. [PMID: 34123670 DOI: 10.7759/cureus.14974] [Reference Citation Analysis]
|
| 20 |
Shin Y, Choi H, Lim S. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study. Diabetes Res Clin Pract 2021;175:108843. [PMID: 33933498 DOI: 10.1016/j.diabres.2021.108843] [Reference Citation Analysis]
|
| 21 |
Lamos EM, Kristan M, Siamashvili M, Davis SN. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Rev Clin Pharmacol 2021;14:837-52. [PMID: 33882758 DOI: 10.1080/17512433.2021.1917374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 22 |
Jichitu A, Bungau S, Stanescu AMA, Vesa CM, Toma MM, Bustea C, Iurciuc S, Rus M, Bacalbasa N, Diaconu CC. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics (Basel) 2021;11:689. [PMID: 33921359 DOI: 10.3390/diagnostics11040689] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 23 |
Chrysavgis L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:893-909. [PMID: 33439540 DOI: 10.1111/jgh.15202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 24 |
Donate-Correa J, Ferri CM, Sánchez-Quintana F, Pérez-Castro A, González-Luis A, Martín-Núñez E, Mora-Fernández C, Navarro-González JF. Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications. Front Med (Lausanne) 2020;7:628289. [PMID: 33553221 DOI: 10.3389/fmed.2020.628289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 25 |
Tobita H, Yazaki T, Kataoka M, Kotani S, Oka A, Mishiro T, Oshima N, Kawashima K, Ishimura N, Naora K, Sato S, Ishihara S. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. J Clin Biochem Nutr 2021;68:173-80. [PMID: 33879970 DOI: 10.3164/jcbn.20-129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 26 |
Cho KY, Nakamura A, Omori K, Takase T, Miya A, Yamamoto K, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. J Diabetes Investig 2021;12:1272-7. [PMID: 33131199 DOI: 10.1111/jdi.13457] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 27 |
Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era? J Diabetes Complications 2020;34:107723. [PMID: 32900588 DOI: 10.1016/j.jdiacomp.2020.107723] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 28 |
Gameil MA, Abdelgawad MS, Bahgat MH, Elsebaie AH, Marzouk RE. Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus. Egypt J Intern Med 2020;32:12. [DOI: 10.1186/s43162-020-00013-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 29 |
Chen JF, Peng YS, Chen CS, Tseng CH, Chen PC, Lee TI, Lu YC, Yang YS, Lin CL, Hung YJ, Chen ST, Lu CH, Yang CY, Chen CC, Lee CC, Hsiao PJ, Jiang JY, Tu ST. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan. PeerJ 2020;8:e9998. [PMID: 33240585 DOI: 10.7717/peerj.9998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 30 |
Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, Carvalho D, Leite-Moreira A. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413. [PMID: 33010191 DOI: 10.1002/dmrr.3413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 31 |
Vincent RK, Williams DM, Evans M. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer? Diabetes Obes Metab 2020;22:2227-40. [DOI: 10.1111/dom.14196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 32 |
Polyzos SA, Kang ES, Boutari C, Rhee E, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020;111:154203. [DOI: 10.1016/j.metabol.2020.154203] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 21.7] [Reference Citation Analysis]
|
| 33 |
Solano-Urrusquieta A, Morales-González JA, Castro-Narro GE, Cerda-Reyes E, Flores-Rangel PD, Fierros-Oceguera R. NRF-2 and nonalcoholic fatty liver disease. Ann Hepatol 2020;19:458-65. [PMID: 31959521 DOI: 10.1016/j.aohep.2019.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 34 |
Aggarwal P, Singh T, Alkhouri N. Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root. Curr Hepatology Rep 2020;19:302-314. [DOI: 10.1007/s11901-020-00533-x] [Reference Citation Analysis]
|
| 35 |
Hsiang JC, Wong VW. SGLT2 Inhibitors in Liver Patients. Clin Gastroenterol Hepatol 2020;18:2168-2172.e2. [PMID: 32428710 DOI: 10.1016/j.cgh.2020.05.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 36 |
Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:430-43. [PMID: 32791578 DOI: 10.3350/cmh.2020.0137] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 37 |
Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 38 |
Bray JJH, Foster-Davies H, Stephens JW. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Res Clin Pract 2020;168:108368. [PMID: 32800932 DOI: 10.1016/j.diabres.2020.108368] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 39 |
Gunhan HG, Imre E, Erel P, Ustay O. EMPAGLIFLOZIN IS MORE EFFECTIVE IN REDUCING MICROALBUMINURIA AND ALT LEVELS COMPARED WITH DAPAGLIFLOZIN: REAL LIFE EXPERIENCE. Acta Endocrinol (Buchar) 2020;16:59-67. [PMID: 32685040 DOI: 10.4183/aeb.2020.59] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 40 |
Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther 2020;11:1849-60. [PMID: 32648108 DOI: 10.1007/s13300-020-00867-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 41 |
Ruscica M, Corsini A, Ferri N, Banach M, Sirtori CR. Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacol Res 2020;159:104916. [PMID: 32445957 DOI: 10.1016/j.phrs.2020.104916] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 42 |
Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul) 2019;34:247-62. [PMID: 31565876 DOI: 10.3803/EnM.2019.34.3.247] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 43 |
Mittag-Roussou V, Wagenpfeil S, Lammert F, Stokes CS. Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. Endocrinol Diabetes Metab 2020;3:e00131. [PMID: 32704556 DOI: 10.1002/edm2.131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 44 |
Kollia C, Antonopoulos AS, Siasos G, Konsola T, Oikonomou E, Gouliopoulos N, Tsigkou V, Papapanagiotou A, Kassi E, Tentolouris N, Katsiki N, Vavuranakis M, Papavassiliou AG, Tousoulis D. Associations between Adiponectin Gene Variability, Proinflammatory and Angiogenetic Markers: Implications for Microvascular Disease Development in Type 2 Diabetes Mellitus? Curr Vasc Pharmacol 2019;17:204-8. [PMID: 29308741 DOI: 10.2174/1570161116666180108113825] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 45 |
Zhang H, Liu J, Zhu X, Li X, Chen H, Wu M, Li C, Ding Y. A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State. Clin Ther 2020;42:892-905.e3. [PMID: 32265061 DOI: 10.1016/j.clinthera.2020.03.007] [Reference Citation Analysis]
|
| 46 |
Donate-Correa J, Luis-Rodríguez D, Martín-Núñez E, Tagua VG, Hernández-Carballo C, Ferri C, Rodríguez-Rodríguez AE, Mora-Fernández C, Navarro-González JF. Inflammatory Targets in Diabetic Nephropathy. J Clin Med 2020;9:E458. [PMID: 32046074 DOI: 10.3390/jcm9020458] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 19.7] [Reference Citation Analysis]
|
| 47 |
Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. J Med Chem 2020;63:5031-73. [PMID: 31930920 DOI: 10.1021/acs.jmedchem.9b01701] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
|
| 48 |
Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sci 2020;240:117090. [PMID: 31765648 DOI: 10.1016/j.lfs.2019.117090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 49 |
Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, Liu J, Liu C, Zhang Y, Ding Y. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐glucose co‐transporter‐2, in people with type 2 diabetes mellitus. Diabetes Obes Metab 2020;22:191-202. [DOI: 10.1111/dom.13887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 50 |
Marjot T, Green CJ, Charlton CA, Cornfield T, Hazlehurst J, Moolla A, White S, Francis J, Neubauer S, Cobbold JF, Hodson L, Tomlinson JW. Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. JGH Open 2020;4:433-40. [PMID: 32514450 DOI: 10.1002/jgh3.12274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 51 |
Tang Y, Sun Q, Bai XY, Zhou YF, Zhou QL, Zhang M. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. Nutr Diabetes 2019;9:32. [PMID: 31685792 DOI: 10.1038/s41387-019-0098-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 52 |
Katsiki N, Mikhailidis DP. Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)? Journal of Diabetes and its Complications 2019;33:107408. [DOI: 10.1016/j.jdiacomp.2019.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 53 |
Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism 2019;101:154001. [PMID: 31672448 DOI: 10.1016/j.metabol.2019.154001] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 54 |
Papakitsou I, Vougiouklakis G, Elisaf MS, Filippatos TD. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clin Pharmacol 2019;11:133-43. [PMID: 31572020 DOI: 10.2147/CPAA.S172353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 55 |
Arase Y, Shiraishi K, Anzai K, Sato H, Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T, Kagawa T. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clin Drug Investig 2019;39:631-41. [PMID: 30993553 DOI: 10.1007/s40261-019-00785-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 56 |
Kinguchi S, Wakui H, Ito Y, Kondo Y, Azushima K, Osada U, Yamakawa T, Iwamoto T, Yutoh J, Misumi T, Aoki K, Yasuda G, Yoshii T, Yamada T, Ono S, Shibasaki-Kurita T, Hosokawa S, Orime K, Hanaoka M, Sasaki H, Inazumi K, Yamada T, Kobayashi R, Ohki K, Haruhara K, Kobayashi Y, Yamanaka T, Terauchi Y, Tamura K. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study). Cardiovasc Diabetol 2019;18:110. [PMID: 31455298 DOI: 10.1186/s12933-019-0912-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 57 |
Kontana A, Tziomalos K. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2019; 25(28): 3664-3668 [PMID: 31391764 DOI: 10.3748/wjg.v25.i28.3664] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 58 |
Dokmak A, Almeqdadi M, Trivedi H, Krishnan S. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World J Hepatol 2019;11:562-73. [PMID: 31388398 DOI: 10.4254/wjh.v11.i7.562] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 59 |
Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019;1:312-28. [PMID: 32039382 DOI: 10.1016/j.jhepr.2019.07.002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 148] [Article Influence: 34.8] [Reference Citation Analysis]
|
| 60 |
Yamashima M, Miyaaki H, Miuma S, Shibata H, Sasaki R, Haraguchi M, Fukushima M, Nakao K. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease. Intern Med 2019;58:1987-92. [PMID: 31308341 DOI: 10.2169/internalmedicine.2566-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 61 |
Katsiki N, Perakakis N, Mantzoros C. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus? Metabolism 2019;98:iii-ix. [PMID: 31301336 DOI: 10.1016/j.metabol.2019.07.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 62 |
Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes 2019;12:1001-12. [PMID: 31308716 DOI: 10.2147/DMSO.S212715] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 63 |
Al-Sofiani ME, Ganji SS, Kalyani RR. Body composition changes in diabetes and aging. J Diabetes Complications 2019;33:451-9. [PMID: 31003924 DOI: 10.1016/j.jdiacomp.2019.03.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 64 |
Nakamura I, Maegawa H, Tobe K, Uno S. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study. Adv Ther 2019;36:923-49. [PMID: 30767112 DOI: 10.1007/s12325-019-0895-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 65 |
Jung CH, Mok JO. The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. J Obes Metab Syndr 2019;28:18-29. [PMID: 31089576 DOI: 10.7570/jomes.2019.28.1.18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 66 |
Yamane M, Matono T, Okano JI, Nagahara R, Matsuki Y, Okamoto T, Miyoshi KI, Sugihara T, Nagahara T, Koda M, Isomoto H. Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model. Yonago Acta Med 2019;62:30-5. [PMID: 30962742 [PMID: 30962742 DOI: 10.33160/yam.2019.03.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 67 |
Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int J Mol Sci 2019;20:E1190. [PMID: 30857216 DOI: 10.3390/ijms20051190] [Cited by in Crossref: 168] [Cited by in F6Publishing: 176] [Article Influence: 42.0] [Reference Citation Analysis]
|
| 68 |
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 350] [Cited by in F6Publishing: 382] [Article Influence: 87.5] [Reference Citation Analysis]
|
| 69 |
Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 2019;45:213-223. [PMID: 30708071 DOI: 10.1016/j.diabet.2019.01.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 16.8] [Reference Citation Analysis]
|
| 70 |
Kawaguchi T, Nakano D, Torimura T. Diabetes in Liver Disease. Alcoholic/Non-Alcoholic Digestive Diseases 2019. [DOI: 10.1007/978-981-13-1465-0_7] [Reference Citation Analysis]
|
| 71 |
Sumida Y, Murotani K, Saito M, Tamasawa A, Osonoi Y, Yoneda M, Osonoi T. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial). Hepatol Res 2019;49:64-71. [PMID: 30051943 DOI: 10.1111/hepr.13236] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
|
| 72 |
Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21:812-821. [PMID: 30447037 DOI: 10.1111/dom.13584] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 73 |
Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes 2018;11:835-43. [PMID: 30568471 DOI: 10.2147/DMSO.S184767] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 74 |
Raschi E, Mazzotti A, Poluzzi E, De Ponti F, Marchesini G. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opin Pharmacother 2018;19:1903-14. [PMID: 30299993 DOI: 10.1080/14656566.2018.1531126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 75 |
Ishihara H, Anai M, Seino H, Kitazawa T, Ohashi H, Ai M, Inoue M, Fujishiro M, Inazawa T, Kuroda H, Yamada M. Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy. Diabetes Ther 2018;9:2117-25. [PMID: 30145651 DOI: 10.1007/s13300-018-0491-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 76 |
Wanner C, Marx N. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 2018;61:2134-9. [PMID: 30132035 DOI: 10.1007/s00125-018-4678-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 77 |
Sattar N, Fitchett D, Hantel S, George JT, Zinman B. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. Diabetologia 2018;61:2155-63. [PMID: 30066148 DOI: 10.1007/s00125-018-4702-3] [Cited by in Crossref: 106] [Cited by in F6Publishing: 87] [Article Influence: 21.2] [Reference Citation Analysis]
|
| 78 |
Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 2018;44:457-64. [PMID: 30266577 DOI: 10.1016/j.diabet.2018.09.005] [Cited by in Crossref: 153] [Cited by in F6Publishing: 159] [Article Influence: 30.6] [Reference Citation Analysis]
|
| 79 |
Miyake T, Yoshida S, Furukawa S, Sakai T, Tada F, Senba H, Yamamoto S, Koizumi Y, Yoshida O, Hirooka M, Kumagi T, Niiya T, Miyaoka H, Masanori A, Matsuura B, Hiasa Y. Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease. Open Med (Wars). 2018;13:402-409. [PMID: 30234161 DOI: 10.1515/med-2018-0059] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 80 |
Garcia de Lucas M, Pérez Belmonte L, Suárez Tembra M, Olalla Sierra J, Gómez Huelgas R. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study. Diabetes & Metabolism 2018;44:373-5. [DOI: 10.1016/j.diabet.2018.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
